Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

New perspectives in Respiratory Syncitial Virus infection.

Del Vecchio A, Ferrara T, Maglione M, Capasso L, Raimondi F.

J Matern Fetal Neonatal Med. 2013 Oct;26 Suppl 2:55-9. doi: 10.3109/14767058.2013.831282. Review.

PMID:
24059554
2.

Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?

Hashmi NA, Cosgrove JF, MacMahon P.

Ir Med J. 2000 Dec;93(9):284.

PMID:
11209917
3.

Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.

American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee.

Pediatrics. 2014 Aug;134(2):415-20. doi: 10.1542/peds.2014-1665. Erratum in: Pediatrics. 2014 Dec;134(6):1221.

4.

Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.

Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, Mueller WD.

Pediatr Infect Dis J. 2012 Jan;31(1):e1-8. doi: 10.1097/INF.0b013e318235455b.

PMID:
21960187
5.

Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age.

Carbonell-Estrany X, Bont L, Doering G, Gouyon JB, Lanari M.

Eur J Clin Microbiol Infect Dis. 2008 Oct;27(10):891-9. doi: 10.1007/s10096-008-0520-8. Epub 2008 Jul 16. Review.

PMID:
18629558
7.

Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.

Robinson KA, Odelola OA, Saldanha I, McKoy N.

Cochrane Database Syst Rev. 2010 Feb 17;(2):CD007743. doi: 10.1002/14651858.CD007743.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD007743.

PMID:
20166098
8.

Palivizumab for the prevention of respiratory syncytial virus infection.

Rogovik AL, Carleton B, Solimano A, Goldman RD.

Can Fam Physician. 2010 Aug;56(8):769-72.

9.

Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.

Oncel MY, Mutlu B, Kavurt S, Baş AY, Demirel N, Akyol M, Erdeve O, Dilmen U.

Turk J Pediatr. 2012 Jul-Aug;54(4):344-51.

PMID:
23692714
10.

The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .

Lanctôt KL, Masoud ST, Paes BA, Tarride JE, Chiu A, Hui C, Francis PL, Oh PI.

Curr Med Res Opin. 2008 Nov;24(11):3223-37. doi: 10.1185/03007990802484234 . Epub 2008 Oct 16.

PMID:
18928643
11.

Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.

Oh PI, Lanctôt KL, Yoon A, Lee DS, Paes BA, Simmons BS, Parison D, Manzi P; Composs Investigators.

Pediatr Infect Dis J. 2002 Jun;21(6):512-8.

PMID:
12182374
12.

Respiratory syncytial virus infection: clinical features, management, and prophylaxis.

Greenough A.

Curr Opin Pulm Med. 2002 May;8(3):214-7. Review.

PMID:
11981311
13.

Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.

Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S.

Pediatr Pulmonol. 2008 Feb;43(2):169-74.

PMID:
18085710
14.

The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut.

Banerji A, Panzov V, Young M, Lee BE, Mamdani M, Giles BL, Dennis M, Morel J, Bisson D, Paes BA, Hui C, Mahony J.

Can Respir J. 2014 May-Jun;21(3):185-9. Epub 2013 Dec 23.

15.

High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention.

Manzoni P, Paes B, Resch B, Carbonell-Estrany X, Bont L.

Early Hum Dev. 2012 May;88 Suppl 2:S34-41. doi: 10.1016/S0378-3782(12)70012-9. Erratum in: Early Hum Dev. 2012 Oct;88(10):845. Mejias, A [removed]; Ramilo, O [removed].

PMID:
22633511
16.

Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis.

Winterstein AG, Eworuke E, Xu D, Schuler P.

Pediatr Pulmonol. 2013 Sep;48(9):874-84. doi: 10.1002/ppul.22711. Epub 2012 Nov 8.

PMID:
23139089
17.
18.

Palivizumab in the prevention of respiratory syncytial virus disease.

Krilov LR.

Expert Opin Biol Ther. 2002 Oct;2(7):763-9. Review.

PMID:
12387675
19.

Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.

Groothuis JR, Hoopes JM, Hemming VG.

Adv Ther. 2011 Feb;28(2):110-25. doi: 10.1007/s12325-010-0101-y. Epub 2011 Feb 4. Review.

PMID:
21318605
20.

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.

Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J; IRIS Study Group.

Pediatr Infect Dis J. 2003 Sep;22(9):823-7.

PMID:
14506376

Supplemental Content

Support Center